血清可溶性CD206可分类抗MDA5抗体阳性皮肌炎相关间质性肺病的严重程度
本研究检测33例抗MDA5抗体阳性临床无肌病性皮肌炎/皮肌炎合并间质性肺病(MDA5-CADM/DM-ILD)患者及36例年龄性别匹配对照的血清可溶性CD206(sCD206)水平,并分析肺组织CD206表达。结果示患者sCD206高于对照(P<0.0001),死亡者高于存活者,sCD206升高与更高死亡率相关(Log-rank P=0.0009),且为独立预后因素;sCD206联合PaO2可将预后分为三组(P<0.005)。
要点
- MDA5-CADM/DM-ILD患者血清sCD206水平显著高于对照(P<0.0001)。
- sCD206升高与更高死亡率相关(Log-rank P=0.0009),为独立预后因素。
- sCD206联合PaO2可将患者预后分为三组(P<0.005)。
核心结论
- MDA5-CADM/DM-ILD患者血清sCD206水平升高,且与不良预后相关,是预测疾病严重程度的潜在生物标志物。
研究设计与样本
- 研究纳入33例MDA5-CADM/DM-ILD患者和36例年龄性别匹配对照,检测血清sCD206浓度并检查肺组织CD206表达。
主要发现
- 患者sCD206水平高于对照(P<0.0001)。
- 33例中10例发生致死性呼吸衰竭,其sCD206浓度显著高于存活者。
- sCD206升高与更高死亡率相关(Log-rank检验,P=0.0009)。
- 年龄性别校正逻辑回归示sCD206为MDA5-CADM/DM-ILD的独立预后因素。
- sCD206联合PaO2评估将预后分为三组(分别P<0.005)。
关键数值与推荐
- 患者与对照sCD206比较P<0.0001。
- 致死性ILD与存活者sCD206比较有显著差异,升高sCD206与更高死亡率相关(Log-rank P=0.0009)。
- sCD206联合PaO2预后分组比较分别P<0.005。
临床怎么用
- 对MDA5-CADM/DM-ILD患者可检测血清sCD206辅助评估预后严重程度。
- sCD206可与PaO2联合用于预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Macrophage-mannose receptor, CD206, is a marker of alternatively activated macrophages. Activated macrophages play key roles in DM. Interstitial lung disease (ILD) is a leading cause of mortality in patients with DM/clinically amyopathic DM (CADM). In particular, patients with the anti-melanoma differential gene 5 antibody (MDA5) frequently develop fatal rapid progressive ILD. This study aimed to evaluate the clinical implications of alternatively activated macrophages in patients with CADM/DM-ILD with anti-MDA5 antibody (MDA5-CADM/DM-ILD). METHODS: We measured serum concentrations of soluble CD206 (sCD206) in 33 patients with MDA5-CADM/DM-ILD and 36 age- and sex-matched control subjects. Expression levels of CD206 in the lungs from MDA5-CADM/DM-ILD were also examined. RESULTS: Patients with MDA5-CADM/DM-ILD had higher levels of sCD206 than those in controls (P < 0.0001). Of the 33 patients, 10 MDA5-CADM/DM-ILD patients developed fatal respiratory failure. Concentrations of sCD206 in patients with fatal ILD cases were significantly higher than those in the survivors, and increased sCD206 levels were associated with a higher mortality rate (Log-rank test, P = 0.0009). Age- and gender-adjusted logistic regression analyses showed that sCD206 was an independent prognostic factor for MDA5-CADM/DM-ILD. Importantly, assessment by sCD206 together with PaO2 successfully divided into three groups by their prognosis (P < 0.005, respectively). Pathological analyses showed accumulations of CD206-positive macrophages in lungs from the fatal case rather than those in the non-fatal cases. CONCLUSIONS: Levels of serum sCD206 are increased in MDA5-CADM/DM-ILD and associated with poor prognosis. sCD206 is a potential biomarker to predict the severity of MDA5-CADM/DM-ILD.
引用
- Horiike Y, Suzuki Y, Fujisawa T, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology (Oxford). 2019. PMID: 31143953. doi:10.1093/rheumatology/kez185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。